These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 29738003)

  • 21. A recent increase in the incidence of prostatic carcinoma in a French population: role of ultrasonography and prostatic specific antigen.
    Ménégoz F; Colonna M; Exbrayat C; Mousseau M; Orfeuvre H; Schaerer R
    Eur J Cancer; 1995; 31A(1):55-8. PubMed ID: 7535076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Descriptive epidemiology of prostate cancer in Japan and Western countries].
    Wakai K
    Nihon Rinsho; 2005 Feb; 63(2):207-12. PubMed ID: 15714967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer screening in a low prevalence population. Is it worth it?
    Arafa MA; Farhat KH; Al-Atawi MA; Rabah DM
    Saudi Med J; 2017 Jul; 38(7):733-737. PubMed ID: 28674719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer incidence and mortality in selected countries of Central Europe.
    Ondrusova M; Muzik J; Kliment J; Gulis G; Ondrus D
    Klin Onkol; 2011; 24(2):126-32. PubMed ID: 21638996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Socioeconomic variation and prostate specific antigen testing in the community: a United Kingdom based population study.
    Morgan RM; Steele RJ; Nabi G; McCowan C
    J Urol; 2013 Oct; 190(4):1207-12. PubMed ID: 23608675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer incidence and mortality in Portugal: trends, projections and regional differences.
    Pina F; Castro C; Ferro A; Bento MJ; Lunet N
    Eur J Cancer Prev; 2017 Sep; 26(5):404-410. PubMed ID: 27483413
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
    Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
    Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer screening in a Saudi population: an explanatory trial study.
    Rabah DM; Arafa MA
    Prostate Cancer Prostatic Dis; 2010 Jun; 13(2):191-4. PubMed ID: 20066007
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
    Stampfer MJ; Jahn JL; Gann PH
    J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
    [No Abstract]   [Full Text] [Related]  

  • 31. [Utilization of screening and treatment of prostate cancer in 2011].
    Tombal B
    Bull Mem Acad R Med Belg; 2011; 166(3-4):170-6; discussion 177. PubMed ID: 22375496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PSA in men in their 40s predicts risk of prostate cancer death.
    Rees J
    Practitioner; 2013 Sep; 257(1764):5. PubMed ID: 24383151
    [No Abstract]   [Full Text] [Related]  

  • 34. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prostate specific antigen].
    Koutani A; Lechevallier E; Coulange C
    Ann Urol (Paris); 1996; 30(5):257-61. PubMed ID: 8975592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia.
    Pan D; McCahy P
    BJU Int; 2012 Apr; 109 Suppl 3():52-6. PubMed ID: 22458495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of dying from early prostate cancer is low regardless of treatment, study finds.
    White C
    BMJ; 2016 Sep; 354():i4984. PubMed ID: 27633860
    [No Abstract]   [Full Text] [Related]  

  • 38. Prostate-specific antigen screening for prostate cancer in older men in the United States of America.
    Black A; Berg CD
    Gerontology; 2012; 58(4):331-6. PubMed ID: 22343605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer screening: and yet it moves!
    Kwiatkowski M; Randazzo M; Kluth L; Manka L; Huber A; Recker F
    Asian J Androl; 2015; 17(3):437-8. PubMed ID: 25532573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features and prevalence of prostate cancer in Aseer, Saudi Arabia.
    Otifi HM; Abdul-Wahab OMS; Al-Shyarba MH; Al Fayi MSS; Al Murea AH; Yacoub E
    Saudi Med J; 2022 Jul; 43(7):755-759. PubMed ID: 35830998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.